SCHEMBL2330141

SCHEMBL2330141

CC(C)(C)OC(=O)N1CC[C@H](Nc2nc(-c3ccccc3O)ncc2-c2ccccc2)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 5/20 0.54
BTK Q06187 1/20 0.51
HPGDS O60760 3/20 0.47
PIK3CD O00329 1/20 0.46
IRAK1 P51617 2/20 0.46
CHEK2 O96017 1/20 0.46
IRAK4 Q9NWZ3 1/20 0.44
EGFR P00533 1/20 0.44
SRC P12931 1/20 0.44
JAK1 P23458 1/20 0.43
CKS1B P61024 1/20 0.43
SKP1 P63208 1/20 0.43
SKP2 Q13309 1/20 0.43
SMARCA2 P51531 1/20 0.43
SMARCA4 P51532 1/20 0.43
PBRM1 Q86U86 1/20 0.43
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
PIM1 P11309 1/20 0.43
PIM2 Q9P1W9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2330139 1.00 USP30 (0.54) USP30BTKHPGDSPIK3CDIRAK1
SCHEMBL2332984 0.87 CHEK2 (0.49) IRAK1CHEK2IRAK4JAK1
SCHEMBL2330725 0.85 USP30 (0.58) USP30BTKHPGDSPIK3CDEGFR
SCHEMBL2330729 0.85 USP30 (0.58) USP30BTKHPGDSPIK3CDEGFR
SCHEMBL9966893 0.82 USP30 (0.48) USP30BTKSMARCA2SMARCA4PBRM1
SCHEMBL2332611 0.80 CHEK2 (0.54) USP30BTKPIK3CDCHEK2SMARCA2
SCHEMBL2332607 0.80 CHEK2 (0.54) USP30BTKPIK3CDCHEK2SMARCA2
SCHEMBL9966892 0.80 CHEK2 (0.52) USP30BTKPIK3CDCHEK2SMARCA2
SCHEMBL2332321 0.79 CHEK2 (0.62) USP30BTKCHEK2SMARCA2SMARCA4
SCHEMBL2332326 0.79 CHEK2 (0.62) USP30BTKCHEK2SMARCA2SMARCA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324226-B2 Therapeutic oxy-phenyl-aryl compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-12-04 US disclosed
US-8324226-B2 Therapeutic oxy-phenyl-aryl compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-12-04 US disclosed
EP-2227460-B1 THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE CANCER REC TECH LTD (GB) 2012-06-20 EP disclosed
EP-2227460-B1 THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE CANCER REC TECH LTD (GB) 2012-06-20 EP disclosed
US-20110201592-A1 Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-08-18 US disclosed
US-20110201592-A1 Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-08-18 US disclosed
EP-2227460-A1 THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2010-09-15 EP disclosed
WO-2009053694-A1 THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201592-A1 Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use CHEK2, CHEK1, PLK1 USP30 2421/4885BTK 688/4885HPGDS 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.